Deadline: 10 July 2023 HSE has received several applications for authorisation for the following substances/uses: - Reference: AFA033-01
Application type: Initial Substances: Chromium trioxide (includes Acids generated from chromium trioxide and their oligomers", when used in aqueous solutions), Sodium dichromate Use: Formulation of mixtures with soluble Cr(VI) compounds for use in aerospace and defence industry and its supply chains for surface treatments. View the details
- Reference: AFA035-01
Application type: Initial Substance: Chromium trioxide (includes Acids generated from chromium trioxide and their oligomers", when used in aqueous solutions) Use: Pre-treatments: Deoxidising, pickling, etching and/or desmutting using chromium trioxide, in aerospace and defence industry and its supply chains. View the details
- Reference: AFA037-01
Application type: Initial Substance: Chromium trioxide (includes Acids generated from chromium trioxide and their oligomers", when used in aqueous solutions) Use: Slurry coating using chromium trioxide in aerospace and defence industry and its supply chains. View the details
- Reference: AFA039-01
Application type: Initial Substances: Chromium trioxide (includes Acids generated from chromium trioxide and their oligomers", when used in aqueous solutions), Sodium chromate Use: Anodise sealing using chromium trioxide and/or sodium chromate in aerospace and defence industry and its supply chains. View the details
- Reference: AFA041-01
Application type: Initial Substances: Chromium trioxide (includes Acids generated from chromium trioxide and their oligomers", when used in aqueous solutions), Sodium dichromate, Potassium dichromate Use: Passivation of (non-Al) metallic coatings using chromium trioxide or sodium dichromate or potassium dichromate in aerospace and defence industry and its supply chains View the details
- Reference: AFA043-01
Application type: Initial Substance: Chromium trioxide (includes Acids generated from chromium trioxide and their oligomers", when used in aqueous solutions) Use: Inorganic finish stripping using chromium trioxide in aerospace and defence industry and its supply chains. View the details
Article 64 in the UK REACH Regulation makes provisions for HSE to obtain and use additional information on possible alternatives or technologies as part of the opinion forming process. HSE has announced public consultations for each of these applications. Details can be viewed at the links above. Any third parties with an interest in these applications are strongly encouraged to share any relevant information. Scientific and technical information on possible alternatives or technologies should be submitted directly to HSE using the commenting webform and templates by 10 July 2023. Non-confidential comments will be published on HSEs website. Details of the adopted opinions, granted UK REACH authorisations and in-progress applications can be found on the HSE website. HSE has opened a call for evidence on formaldehyde and formaldehyde releasers: HSE, with the UK Health and Security Agency (UKHSA), is preparing an RMOA to examine exposure of the general public to formaldehyde from formaldehyde releasers in articles. To inform this RMOA, HSE has opened a call for evidence and invites interested parties to respond with general information and information on specific topics. HSE is particularly interested in: - the manufacture, import and use of articles that have the potential to release formaldehyde to indoor air during their service life;
- the rate of emissions of formaldehyde from these articles;
- actions that may be taken to reduce exposure to formaldehyde from these sources; and,
- the levels of formaldehyde that can be generated in indoor settings from processes which can release formaldehyde such as cooking, use of candles and indoor domestic combustion such as woodburning stoves and ethanol fires.
View the calls for evidence on HSE's website. The RMOA will assess the best regulatory approach for GB. It will determine the use profile for the substances concerned, whether any of these uses are creating a risk to human health and / or the environment, and will identify the best regulatory approach to manage any identified risks. |